BioGaia AB (publ) (LON: 0GTN)
London
· Delayed Price · Currency is GBP · Price in SEK
116.50
+0.60 (0.52%)
At close: Jan 21, 2025
BioGaia AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 1,356 | 1,297 | 1,104 | 785.11 | 747.08 | 768.35 | Upgrade
|
Revenue Growth (YoY) | 6.49% | 17.44% | 40.61% | 5.09% | -2.77% | 3.57% | Upgrade
|
Cost of Revenue | 358.07 | 346.32 | 302.03 | 202.16 | 200.16 | 204.35 | Upgrade
|
Gross Profit | 997.6 | 950.19 | 801.93 | 582.95 | 546.92 | 564 | Upgrade
|
Selling, General & Admin | 438.28 | 402.51 | 360.62 | 230.76 | 197.76 | 208.94 | Upgrade
|
Research & Development | 100.78 | 106.78 | 106.81 | 105.47 | 104.66 | 105.05 | Upgrade
|
Other Operating Expenses | - | - | - | 0 | - | - | Upgrade
|
Operating Expenses | 539.06 | 509.28 | 467.42 | 336.23 | 302.43 | 313.99 | Upgrade
|
Operating Income | 458.54 | 440.91 | 334.51 | 246.72 | 244.49 | 250.01 | Upgrade
|
Interest Expense | -16.59 | -15.8 | -5.39 | -1.13 | -0.72 | -0.67 | Upgrade
|
Interest & Investment Income | 49.53 | 41.53 | 7.96 | 0.11 | 0.16 | 0.42 | Upgrade
|
Currency Exchange Gain (Loss) | -7.21 | 1.82 | 26.79 | 11.14 | -17.43 | -7.5 | Upgrade
|
Other Non Operating Income (Expenses) | - | - | 3.56 | - | - | - | Upgrade
|
EBT Excluding Unusual Items | 484.28 | 468.46 | 367.44 | 256.84 | 226.5 | 242.26 | Upgrade
|
Merger & Restructuring Charges | - | - | - | -4.23 | - | - | Upgrade
|
Other Unusual Items | -1.56 | 0.38 | 80.17 | 0.1 | 1.08 | - | Upgrade
|
Pretax Income | 431.52 | 468.83 | 447.61 | 252.71 | 227.58 | 242.26 | Upgrade
|
Income Tax Expense | 94.71 | 103.48 | 73.84 | 56.44 | 47.85 | 55 | Upgrade
|
Earnings From Continuing Operations | 336.82 | 365.35 | 373.77 | 196.27 | 179.73 | 187.26 | Upgrade
|
Net Income to Company | 336.82 | 365.35 | 373.77 | 196.27 | 179.73 | 187.26 | Upgrade
|
Minority Interest in Earnings | - | - | - | - | - | 0.09 | Upgrade
|
Net Income | 336.82 | 365.35 | 373.77 | 196.27 | 179.73 | 187.35 | Upgrade
|
Net Income to Common | 336.82 | 365.35 | 373.77 | 196.27 | 179.73 | 187.35 | Upgrade
|
Net Income Growth | -23.00% | -2.25% | 90.44% | 9.20% | -4.07% | -12.82% | Upgrade
|
Shares Outstanding (Basic) | 101 | 101 | 101 | 101 | 89 | 87 | Upgrade
|
Shares Outstanding (Diluted) | 101 | 101 | 101 | 101 | 89 | 87 | Upgrade
|
Shares Change (YoY) | 0.07% | - | - | 13.11% | 2.18% | 0.80% | Upgrade
|
EPS (Basic) | 3.33 | 3.62 | 3.70 | 1.94 | 2.01 | 2.14 | Upgrade
|
EPS (Diluted) | 3.33 | 3.62 | 3.70 | 1.94 | 2.01 | 2.14 | Upgrade
|
EPS Growth | -23.02% | -2.22% | 90.72% | -3.64% | -6.10% | -13.52% | Upgrade
|
Free Cash Flow | 365.19 | 377.4 | 301.03 | 215.5 | 205.18 | 115.54 | Upgrade
|
Free Cash Flow Per Share | 3.61 | 3.74 | 2.98 | 2.13 | 2.30 | 1.32 | Upgrade
|
Dividend Per Share | 1.900 | 1.900 | 1.450 | 0.730 | 0.682 | 0.750 | Upgrade
|
Dividend Growth | 31.03% | 31.03% | 98.63% | 7.04% | -9.07% | -7.41% | Upgrade
|
Gross Margin | 73.59% | 73.29% | 72.64% | 74.25% | 73.21% | 73.40% | Upgrade
|
Operating Margin | 33.82% | 34.01% | 30.30% | 31.43% | 32.73% | 32.54% | Upgrade
|
Profit Margin | 24.85% | 28.18% | 33.86% | 25.00% | 24.06% | 24.38% | Upgrade
|
Free Cash Flow Margin | 26.94% | 29.11% | 27.27% | 27.45% | 27.46% | 15.04% | Upgrade
|
EBITDA | 473.09 | 455.44 | 348.71 | 259.98 | 255.16 | 259.58 | Upgrade
|
EBITDA Margin | 34.90% | 35.13% | 31.59% | 33.11% | 34.15% | 33.78% | Upgrade
|
D&A For EBITDA | 14.55 | 14.53 | 14.2 | 13.25 | 10.66 | 9.57 | Upgrade
|
EBIT | 458.54 | 440.91 | 334.51 | 246.72 | 244.49 | 250.01 | Upgrade
|
EBIT Margin | 33.82% | 34.01% | 30.30% | 31.43% | 32.73% | 32.54% | Upgrade
|
Effective Tax Rate | 21.95% | 22.07% | 16.50% | 22.33% | 21.03% | 22.70% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.